A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.
Cell Reports March 28, 2023 Vern Lewis, Emma M. Bonniwell, Janelle K. Lanham et al. 129 citations
Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT2A, and does not induce the head-twitch response (HTR) in...